KOL Resume for Hana Linkova
Hana Linkova: Influence Statistics
Open the FULL List in Excel
Prominent publications by Hana Linkova
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA
[ PUBLICATION ]
BACKGROUND: Adverse cardiac remodeling is a major risk factor for the development of post myocardial infarction (MI) heart failure (HF). This study investigates the effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute ST-segment-elevation myocardial infarction (STEMI).
METHODS: In this double-blind, randomized, placebo-controlled trial patients with first STEMI were eligible. To preferentially enrich patients at high risk of adverse remodeling, main ...
|Known for Cardiac Remodeling | Myocardial Infarction | Chymase Inhibitor | Patients Randomized | Fulacimstat Tolerated|
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2
[ PUBLICATION ]
BACKGROUND: Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation factor XIa (FXIa) inhibitor, might reduce thrombosis with minimal effect on haemostasis. We aimed to determine the optimal dose of asundexian and to compare the incidence of bleeding with that of apixaban in patients with atrial fibrillation.
METHODS: In this randomised, double-blind, phase 2 ...
|Known for Atrial Fibrillation | Factor Xia|
Key People For Cardiac Remodeling
Hana Linkova:Expert Impact
Concepts for whichHana Linkovahas direct influence:Cardiac remodeling, Chymase inhibitor, Inhibitor fulacimstat, Factor xia, Fulacimstat tolerated, Effects chymase.
Hana Linkova:KOL impact
Concepts related to the work of other authors for whichfor which Hana Linkova has influence:Cardiac remodeling, Sacubitril valsartan, Primary pci, Factor xia, Alternate component, Chymase inhibitor, Nash oxidative stress.
Is this your profile? Claim your profile Copy URL Embed Link to your profile